Anzu®’s Post

[INNOVATION UPDATE] Donanemab to Treat Early Alzheimer’s disease Toxic accumulations of amyloid-beta (Aβ) protein in the brain, often called plaques, are thought to be key contributors to Alzheimer’s disease (AD) pathology. Donanemab (Kisunla) is a monoclonal antibody designed to bind to Aβ plaques and promote their clearance from the brain, thus slowing cognitive decline. Donanemab was approved by the U.S. Food and Drug Administration to treat patients with early symptomatic AD, including mild cognitive impairment as well as the mild dementia stage of AD, who have confirmed amyloid pathology. Want to learn more about this novel therapy? View the latest Emerging Health Care Innovation Brief: Emerging Healthcare Innovation Brief Volume 2 - Issue 15 (https://hubs.la/Q02KCv540) #alzheimersdisease #earlyalzheimers #dementia #neurology#patientcare #healthcare #innovation #horizonscanning #ecri

Now On-Demand! Join us for this sponsored webinar hosted by our friends at NeuroSeriesLive. National Infusion Center Association (NICA)'s Director of Clinical Education, Monica Parsons, RN, BSN, will join Sarah Harlock, MBA, Director, Integrative Center for Memory at DENT Neurologic Institute, and Bela Ajtai, MD, PhD, Attending Neurologist, DENT Neurologic Institute discuss biologic infusion therapies, including anti-amyloid monoclonal antibodies that are now available for the treatment of people with mild cognitive impairment (MCI) and early Alzheimer’s disease. Early diagnosis, an understanding of new biomarkers, and strategies to address adverse events are crucial to fully leveraging the potential of these new therapies in the clinic and ensuring that each patient receives the right treatment. Review the importance of strategies for identifying and diagnosing patients with MCI and early Alzheimer’s disease. Learn more: https://lnkd.in/gUWFFH6V #infusionprovider #medicalprovider #infusion #infusioncenter #infusionnurse #infusiondeliverychannel #medicalinfusionprovider

🚀 Transforming Clinical Trials for Neurodegenerative Diseases! 🧠 We are excited to share the latest advancements in clinical trial management for neurodegenerative and neuromuscular diseases, thanks to the innovative AnzuBridge Clinical Data Management System (CDMS)! 🔍 Why It Matters: Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS present significant challenges in clinical trials due to their complex and varied progression. Precise and standardized evaluations are crucial for developing effective treatments. ✨ Introducing AnzuBridge CDMS: AnzuBridge CDMS revolutionizes clinical trials with its state-of-the-art features: 📽️ Patented video bookmarking and clipping for streamlined evaluations 🛡️ Enhanced data accuracy and security 📊 Efficient review processes and comprehensive data analysis 📈 Impact on Patient Outcomes: By ensuring precise, standardized, and efficient evaluations, Anzu® CDMS significantly improves the reliability of trial results, ultimately leading to better patient outcomes. Join us in advancing research and improving lives. Learn more about how AnzuBridge CDMS can optimize your clinical trials. 👉 Read the full article and discover the future of clinical trial management! https://lnkd.in/eeFc3-qu #NeurodegenerativeDiseases #ClinicalTrials #HealthcareInnovation #AnzuBridgeCDMS #MedicalResearch #PatientCare

In 2023, several research findings related to endometriosis have emerged. Some of the latest advancements include: 1. A study published in Science Translational Medicine found that endometriosis may be caused by a bacterial infection. This discovery could potentially lead to new treatments and a better understanding of the condition. 2. A global study revealed compelling evidence of a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis. This finding could help researchers develop more targeted treatments for endometriosis. 3. A potential new treatment for endometriosis is being tested in a groundbreaking clinical trial involving 100 women in Edinburgh and London. The trial aims to assess whether the drug dichloroacetate helps relieve pain, which could be the first non-hormonal, non-surgical treatment for endometriosis. 4. Research has shown that pelvic floor therapy could be key to tackling endometriosis-induced pain. A 2021 study showed that incorporating pelvic floor therapy as part of a lifestyle could help women with deeply infiltrative endometriosis (DIE) – a type of endometriosis that can invade the pelvic cavity. These findings contribute to the ongoing research and development of new treatments and interventions for managing endometriosis, a condition that affects around 190 million women and girls globally. #EndometriosisAwareness #EndoWarrior #EndoStrong #EndoCommunity #EndoSupport #EndoSisters #EndoAdvocate #EndoLife #EndoAware #EndoFighter #EndoPain #EndoAwarenessMonth #EndoResearch #EndoHealth #EndoAwarenessCampaign

Imagine the scenario: a company is developing a groundbreaking medication for Alzheimer's disease, but the clinical trial includes patients with other forms of dementia due to misclassification. The result? The medication, which might have been effective for Alzheimer's, fails because it's tested on an entirely different condition. This is not just a hypothetical situation – it's a challenge the healthcare system faces, leading to significant setbacks in dementia drug research. However, with the precise identification of patient populations through structural MRI and brain volumetry, we can now accurately classify patients even in the early stages of neurodegenerative diseases. This accuracy is more than just a technical achievement; it's a leap forward in ensuring the right patients are enrolled in clinical trials, enhancing the potential success of new medications. By refining our diagnostic capabilities, we can ensure that clinical trials are more targeted, efficient, and likely to yield meaningful results. The implications of this are immense for pharmaceutical companies and the medical community. By embracing these objective measures, we're not just improving the accuracy of clinical studies; we're paving the way for more effective treatments and, ultimately, offering hope to millions affected by these debilitating conditions. What do you think? Is there a need for better objective methods in neurodegenerative diseases? Join me in discussing how these technologies are reshaping the landscape of neurodegenerative disease research and what this means for future therapeutic developments. #Dementia #ClinicalResearch #StructuralMRI #BrainVolumetry 

Aug 31, 2024, 11:09 Edward D. Esplin: Clinician Responses to #Germline #GeneticTesting in #ProstateCancer Management Edward D. Esplin, Clinical Geneticist at Invitae, shared on X: “Up to 17% of #prostatecancer patients have PGVs with #germlinetesting 36% of universally tested PC #patients had positive health outcomes 2/2 #genetictesting results Neal Shore et al. ‘This study supports #universal #germline #genetictesting for #patients with #prostatecancer, and it demonstrates the clinical utility of #germline #genetictesting results—both positive and negative—for…the care of #patients and their families.’” https://lnkd.in/g_jjfT5x American Urological Association https://lnkd.in/gYvBPPiE OncoDaily #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention #AI #precisioninterpretation Invitae Labcorp

Multiple Sclerosis (MS) is a chronic disease characterized by the dysregulation of the immune system, which leads to an abnormal immune response that targets and damages the central nervous system. 🧠 Immunomodulatory treatments for MS aim to adjust the immune system’s activity to reduce inflammation and limit further neurological damage. 💊 Since 2014, several immunomodulatory therapies with modest yet clinically significant effects have been approved for the management of progressive MS, particularly for those with active inflammatory disease. Notably, the ORATORIO trial for ocrelizumab (Ocrevus) demonstrated a significant reduction in disability progression in primary progressive MS, while the EXPAND trial for Siponimod (Mayzent) showed reductions in both disability progression and relapse rates in secondary progressive MS patients compared to placebo. 📉 These therapies represent a range of strategies designed to manage MS by modifying immune responses and mitigating inflammation. Ongoing research and advancements in treatment are expected to enhance outcomes and provide new hope for those affected by MS. 🌟 ⁉️ Are you looking for excellence in a CRO Contact us! 📞💻 ____________________________________________________________________ Leading clinical trials with detail, efficiency, and excellence ♾️Share if others could benefit from this too! 🔔 To follow Hemex click the bell on the profile. #NeurologicalDisease #MultipleSclerosis #MedicalResearch #CRO #ClinicalDevelopment #BioTech

🧬 Spinal Muscular Atrophy (SMA): Hope Through Clinical Trials 💪 Spinal Muscular Atrophy (SMA) is a rare genetic disease that affects motor nerve cells in the spinal cord, leading to progressive muscle weakness and, in severe cases, difficulty in breathing and swallowing. 🔬 The importance of clinical trials: Clinical trials have been crucial in advancing SMA treatments, opening doors to new therapies that improve the quality of life for patients. Thanks to ongoing research, we’ve seen the development of innovative treatments that slow the progression of the disease and, in some cases, allow affected children to reach milestones that were previously unattainable. 🌟 The path to a cure: While there is still no definitive cure, each clinical trial brings us closer. Participating in these trials not only provides access to potential treatments but also contributes to the global understanding of SMA, benefiting future generations. 💙 Your support matters: Raising awareness about the importance of clinical trials can make a big difference. Together, we can support the SMA community and promote research to find a cure! #SpinalMuscularAtrophy #ClinicalTrials #MedicalResearch #HopeForSMA #ScienceAndHealth #TheraResearch

Clinical guidelines and practice updates took center stage at the live AGA Postgraduate (PG) Course in Washington, D.C earlier this year. Now, you can catch up on the clinical and research innovations you may have missed with the AGA PG Course OnDemand. Our virtual platform allows you to easily filter through content by topic and with CME testing integrated into the course, it’s easier than ever to focus on what's most relevant to your work. Explore hours of clinical guidance covering the topics that matter to you, including: ✅ Early detection of colon and pancreatic cancers and how AI is advancing prevention. ✅ Approaches to chronic gastrointestinal pain syndromes. ✅ The obesity pandemic and what you can do about it. ✅ IBD, GERD and hepatology developments over the past year. Practical, easy-to-implement changes are just one click away — complete your purchase today: https://ow.ly/lg5p50SXJzk